Evolving trends in dupilumab use for chronic rhinosinusitis with nasal polyps (CRSwNP): a 4-year cohort analysis
Abstract Chronic rhinosinusitis with nasal polyps (CRSwNP) affects up to 4.5% of the population and is frequently driven by type 2 inflammation. Dupilumab, targeting IL‑4 and IL‑13 pathways, was approved in 2019 as the first biologic for CRSwNP in Germany. This single-center, retrospective study ana...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Portfolio
2025-12-01
|
| Col·lecció: | Scientific Reports |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1038/s41598-025-17787-4 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|